Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis.

ABSTRACT:

Background

Atezolizumab combined with either bevacizumab (atezo-beva) or cabozantinib (atezo-cabo) has been granted approval for the treatment of advanced hepatocellular carcinoma (HCC). Given the current uncertainty among physicians and patients regarding the optimal choice between these two strategies, it becomes imperative to conduct a cost-effectiveness analysis to compare their relative benefits.

Objective

Assessing the cost-effectiveness of atezo-beva compared to atezo-cabo in the treatment of advanced HCC.

Methods

Both the network treatment comparison and cost-effectiveness analysis included patients from the IMbrave150 and the COSMIC-312 phase 3 randomized clinical trials. The network treatment comparison which included 761 patients was carried out, and a cost

SUBMITTER: Xiang H 

PROVIDER: S-EPMC12674557 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature